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Targeted therapyHost defense-derived peptides have emerged as a novel strategy for the development of alternative anticancer
therapies. In this study we report on characteristic features of human lactoferricin (hLFcin) derivatives which
facilitate speciﬁc killing of cancer cells of melanoma, glioblastoma and rhabdomyosarcoma compared with
non-speciﬁc derivatives and the synthetic peptide RW-AH. Changes in amino acid sequence of hLFcin providing
9–11 amino acids stretched derivatives LF11-316, -318 and -322 only yielded low antitumor activity. However,
the addition of the repeat (di-peptide) and the retro-repeat (di-retro-peptide) sequences highly improved cancer
cell toxicity up to 100% at 20 μM peptide concentration. Compared to the complete parent sequence hLFcin the
derivatives showed toxicity on the melanoma cell line A375 increased by 10-fold and on the glioblastoma cell
line U-87mg by 2–3-fold. Reduced killing velocity, apoptotic blebbing, activation of caspase 3/7 and formation
of apoptotic DNA fragments proved that the active and cancer selective peptides, e.g. R-DIM-P-LF11-322, trigger
apoptosis, whereas highly active, though non-selective peptides, such as DIM-LF11-318 and RW-AH seem to kill
rapidly via necrosis inducing membrane lyses. Structural studies revealed speciﬁc toxicity on cancer cells by
peptide derivatives with loop structures, whereas non-speciﬁc peptides comprised α-helical structures without
loop.Model studieswith the cancermembranemimic phosphatidylserine (PS) gave strong evidence that PS only
exposed by cancer cells is an important target for speciﬁc hLFcin derivatives. Other negatively chargedmembrane
exposed molecules as sialic acid, heparan and chondroitin sulfate were shown to have minor impact on peptide
activity.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cancer is still a leading cause of death worldwide. In the year 2012,
more than 14.1 million people all over the world were diagnosed with
cancer (http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx) resulting
in 8.2 million deaths. Since the 1940s and the development of the ﬁrst
chemotherapeutics [1], much progress has beenmade regarding cancer
treatment using chemotherapy, surgery, radiation, targeted therapy and
combinations thereof. Still, cancer is not curative in/for many cases ande Fund (FWF; grant no. P24608-
osciences, Biophysics Division,
ustria.
dagmar.zweytick@uni-graz.at
. This is an open access article undertherapy is usually accompanied by severe side effects due to non-
speciﬁcity for tumor cells. Besides, resistance, formation of metastases
leads to poor treatability and bad prognosis as amongst others described
for malignant melanoma or glioblastoma, cancers to skin or brain.
Hence, many cancer types including malignant melanoma [2,3] show
only weak sensitivity to chemotherapy. New approaches of molecular
targeted therapy and immunotherapies, as the 2011 FDA approved
Ipilimumab only yield a 12.7 months median survival either [4].
Glioblastoma is the most prevalent primary brain tumor and prognosis
for this grade IV tumor implicates a 2-year-survival rate of only 5% [5]
despite intensive research. Applied therapies like radical surgery, radio-
therapy or chemotherapywith the alkylating agent Temozolomide only
prolong median survival to 15 months after diagnosis [6].
In search of novel anticancer agents host defense peptides and
derivatives thereof have emerged as potential alternative anticancer
therapeutics offering many advantages over other therapies [7]. Hostthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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species (e.g. mammals, insects, and amphibians) aremostly cationic but
amphipathic, targeting the cell membrane by electrostatic interactions
with anionic molecules at the cell surface. Because of their mode of
action and speciﬁcity — the cell membrane being the major target —
resistance and cytotoxicity is less likely to occur [8–10] and thus, in
addition they are expected to cause fewer side effects.
Regarding the mode of action of the speciﬁc killing by anticancer
peptides two general mechanisms, triggering necrosis or apoptosis by
anticancer peptides as a consequence of their membrane related mode
of killing, have been discussed [10–12]. Both killing, based on necrosis
via cell membrane lyses and apoptosis via themitochondrial lytic effect,
seem to be dependent on the presence of anionic lipids. The negatively
charged phospholipid phosphatidylserine (PS) located in the outer
leaﬂet of cancer cell plasma membranes can represent such a speciﬁc
target [13], as cardiolipin, a major anionic phospholipid of the mito-
chondrial membrane. Other negatively charged molecules, which are
also exposed on cancer plasma membranes such as sialic acid, heparin
and chondroitin sulfate may play a minor role as peptide targets, since
present on neoplastic and non-neoplastic cells, though to different
extent [7]. Contrariwise these negatively charged molecules might
even be able to protect cells from the interaction with cationic peptides
by binding and limiting the access to the plasma membrane [14].
As mentioned above a speciﬁc target is provided by cancer cells in
the form of the negatively charged phosphatidylserine (PS) which is
exposed on the outer leaﬂet of the cancer cell membrane during
malignant transformation [15–20]. In non-cancerous cells the cell sur-
face comprises an overall neutral charge due to their main components:
the zwitterionic phosphatidylcholine (PC) and sphingomyelin (SM).
Phosphatidylserine together with the major part of phosphatidyletha-
nolamine (PE) assembles the inner leaﬂet of eukaryotic non-cancerous
plasma membranes [21]. This lipid asymmetry of the two membrane
leaﬂets is well documented [22,23] and is maintained by an ATP-
dependent aminophospholipid translocase [24]. The loss of membrane
asymmetry was shown for several cancer types, including metastases,
promising to be a general marker of cancer cells and target for therapy
by peptides [13,15–18,20,25,26].
In our study, we focused on the human host defense peptide
lactoferricin (hLFcin) which is known to exhibit antimicrobial, antiviral,
anti-inﬂammatory and anticancer activities (for a review see [27]).
Human lactoferricin comprises amino acid residues 1–45 of the N-
terminus of human lactoferrin (hLF). LF11, an 11 amino acid fragment
of hLFcin has been optimized regarding its activity against bacterial
[28–30] and cancer membranes [31]. Within this study we report
about 3 groups of peptides. The groups are derived from the amino
acid stretch 21–31 of hLFcin comprising short non-cancer active
peptides, longer cancer active and selective di- (retro) peptides and
active but non-selective (di-) peptides.
2. Materials and methods
2.1. Peptides
The hLFcin derived peptides LF11-322 (PFWRIRIRR-NH2, M =
1298.6 g/mol), its di-retro-peptide R-DIM-P-LF11-322
(PFWRIRIRRPRRIRIRWFP-NH2, M = 2677.4 g/mol), LF11-316
(RWKRINRQWF-NH2, M = 1488.8 g/mol), its di-retro-peptide R-DIM-
LF11-316 (RWKRINRQWFFWQRNIRKWR-NH2, M = 2960.5 g/mol),
LF11-318 (FWQRRIRRWRR-NH2, M= 1715.0 g/mol), its di-peptide DIM-
LF11-318 (FWQRRIRRWRRFWQRRIRRWRR-NH2, M = 3413.1 g/mol),
the di-retro-peptide R-DIM-LF11-337 (PFWRRRIRIRRRRIRIRRRWFP-
NH2, M = 3204.9 g/mol) and the synthetic peptide RW-AH
(WWRRWWRRWRRWWRRWWR-NH2, M = 3098.4 g/mol) were
purchased from NeoMPS, Inc. (San Diego, CA, USA). The purities were
N97% as determined by RP-HPLC. Human lactoferricin (hLFcin) (amino
acid 37–61 of human lactoferrin) (TKCFQWQRNMRKVRGPPVSCIKRDS),with disulﬁde bond between Cys3 and Cys20 was purchased from
AnaSpec, Inc. (Fremont, CA, USA). Peptides were dissolved in Acetic
acid (0.1%, v/v) at concentrations of 3 mg/ml. Peptide solutions were
stored at 4 °C and concentrations were determined by measurement
of UV-absorbance of tryptophan at 280 nm.
2.2. Cell lines and cultures
Melanoma cell lines fromprimary (SBcl-2) andmetastatic (WM164)
lesions were maintained in RPMI 1640 medium with GlutaMAX™
(Gibco®, Life Technologies, USA), supplemented with 2% FBS (fetal
bovine serum; Gibco®). Rhabdomyosarcoma cell line (TE671)
purchased from ECAAC (Health Protection Agency Culture Collections
Salisbury, UK) is cultured in Dulbecco's Modiﬁed Eagle Medium with
GlutaMAX™ (DMEM, Gibco®, Life Technologies, USA) with addition of
10% FBS (Gibco®). The melanoma cell line A375 purchased from ATCC
(American Type Culture Collection, Manassas, Virginia, USA) the
glioblastoma cell line U-87mg purchased from CSL (Cell Line Service,
Eppelheim, Germany) were cultured in Dulbecco's Modiﬁed Eagle
Medium with GlutaMAX™ (DMEM, Gibco®, Life Technologies, USA)
with addition of 10% FBS (Gibco®) and Minimum Essential Media
with GlutaMAX™ (MEM Gibco®) supplemented with 10% FBS
(Gibco®), 0.1 mM non-essential amino acids (NEAA; Gibco®) and
1.0 mM sodium pyruvate (Gibco®), respectively. Human melanocytes
used as healthy control cells were isolated from foreskin as previously
described [31]. Melanocytes were cultured in melanocytes growth
medium (PromoCell GmbH, Heidelberg, Germany). Normal human
dermal ﬁbroblasts purchased from PromoCell GmbH were cultured in
ﬁbroblast growth medium 2 (PromoCell GmbH). All cells were kept in
a 5% CO2 atmosphere at 37 °C. At 90% conﬂuence cells were passaged
with accutase (Gibco®, Life Technologies, USA). All cell cultures were
periodically checked for mycoplasma.
2.3. Spectroscopy in vitro
Toxicity studies on cells were performed using Glomax Multi +
detection system (Promega, Madison, WI, USA).
2.3.1. PI-uptake assay
Cells were collected, resuspended in media and diluted to a concen-
tration of 106 cells/ml. Aliquots of 105 cells were incubated with
peptides for up to 8 h at 37 °C and 5% CO2. For the measurement of
the inﬂuence of Ca2+ on peptide induced PI-uptake Ca2+ was present
in the respective media at the following concentrations: 0.4 M
(standard level in RPMI 1640 medium), 2.0 M, 5.0 M, 10.0 M and
20.0 M. PI was added and cells were again incubated for 5 min at
room temperature in the dark. Excitation and emission wavelengths
were 536 nm and 617 nm, respectively. For every experiment with
every cell line and every peptide the 0% value (0 μM peptide) and
100% value (addition of Triton X-100) was analyzed. Each experiment
was repeated 7 times and medium cytotoxicity was calculated as
described previously [31].
2.3.2. Cleavage of sialic acid
To remove sialic acid moieties from the cell surface [32,33], the cells
were incubated for 45 min at 37 °C in PBS buffer with 0.1 U/ml
neuraminidase from Clostridium perfringens purchased from Sigma-
Aldrich (Deisenhofen, Germany). The cells were washed twice with
buffer, resuspended in media and then incubated with peptides, PI-
uptake was determined subsequently as in the absence of sialic acid
cleavage (see PI-uptake assay).
2.3.3. Addition of exogenous heparin and chondroitin sulfate
Cells were incubated with 20 μM peptides in the presence and
absence (control) of 1 μg/ml and 10 μg/ml heparin (Sigma-Aldrich,
Deisenhofen, Germany) or chondroitin sulfate (Sigma-Aldrich,
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as in the absence of heparin or CS (see PI-uptake assay).
2.3.4. MTS viability assay
Cell proliferationwasmeasured by using CellTiter 96®Aqueous One
Solution Cell Proliferation assay (Promega). Cells were plated in 96-well
plates and grown until conﬂuence in respective medium containing 2%
serum at maximum to avoid interference with the MTS compound.
Peptides were added to a ﬁnal concentration of 5–100 μM. After incuba-
tion for 24 h at 37 °C (5% CO2) MTS [3-(4,5-dimethylthiazol-2yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium]-phenozine
methosulfate solution (20 μl/well) was added and cells were again
incubated for 2 h at 37 °C (5% CO2). The MTS compound is bioreduced
by cells into a colored formazan product that is soluble in tissue culture
medium. The quantity of the formazan product as measured by
the amount of 490 nm absorbance is directly proportional to the
number of living cells in culture. Data are calculated as a percentage
of the control (untreated) samples and represent the average of
three wells in one experiment which was repeated three times per
cell line.
2.3.5. Caspase-3/7 assay/LDH release assay
Peptide induced caspase-3/7 activity in themelanomacell lines SBcl-
2 and A375 and the glioblastoma cell line U-87mg was determined
using the Caspase-Glo® 3/7 Assay (Promega). 2 ∗ 105 cells/ml were
seeded in white 96-well plates with clear bottom and grown for 48 h
at 37 °C (5% CO2). Peptides were added to different concentration for
2–4 h. Caspase solution was added to a ﬁnal 1:1 ratio for 30 min at
37 °C. Luminescence intensity was recorded using Glomax Multi +
detection system (Promega). Caspase-3/7 activity was calculated as a
multiple of untreated cells.
To determine the amount of nonviable cells the CytoTox-ONE™
Homogeneous Membrane Integrity Assay (Promega), which monitors
LDH release (lactate dehydrogenase), was used following the standard
protocol. The CytoTox-ONE™ reagent was added to a ﬁnal 1:1 ratio for
10 min at room temperature. The reaction was stopped by adding the
stop solution. Fluorescence intensity was recorded at 590 nm (excita-
tion 560 nm) using Glomax Multi + detection system (Promega).
Percentage of LDH release was calculated as described for PI toxicity.
Data were calculated as an average of at least three experiments.
2.4. Fluorescence microscopy
Experiments were performed on a Leica DMI6000 B with IMC in
connection with a Leica DFC360 FX camera and AF 6000 software
(Leica Microsystems, Vienna, Austria).
2.4.1. PI-uptake
Cells (1–5 × 104) were seeded on Ibidi μ-Slide 8 wells and grown in
300 μl media for 2–3 days to a conﬂuent layer. Propidium iodide (PI, 2 μl
of 50 μg/ml in PBS, Biosource, Camarillo, CA, USA)was added to thewell
and cell statuswas checked after 5min of incubation in the dark at room
temperature. Then, peptides were added to the desired concentration
and peptide effect was followed immediately. Pictures were taken
every 5 or 15min for up to 8 h from the same section of cells. Excitation
and emission wavelength were as follows: PI excitation, 535 nm and
emission, 617 nm.
2.4.2. TUNEL staining (in situ direct DNA fragmentation)
DNA fragmentation was detected using In situ Direct DNA Fragmen-
tation (TUNEL) Assay Kit (Abcam, Cambridge, GB). Cells (5 × 104) were
seeded on Ibidi μ-Slide 8 wells and grown in 300 μl media for one day to
a conﬂuent layer. Peptides were added to the desired concentration and
incubated for 2–4 h at 37 °C and 5% CO2. Cells were then ﬁxed using 1%
(w/v) paraformaldehyde in PBS and kept in 70% (v/v) ethanol at−20 °C
until use. Cells were stained according to the assay protocol. DNAfragmentation was monitored by ﬂuorescence microscopy. Apoptotic
cells show green staining through FITC-labeling (Ex 495 nm, Em
519 nm). Additionally, PI counterstaining was used.
2.5. Circular dichroism spectroscopy
Measurements were performed on a Jasco J 715 Spectropolarimeter
(Jasco, Gross-Umstadt, Germany) at room temperature using quartz
cuvetteswith an optical path length of 0.02 cm. The CD spectraweremea-
sured between 260 nm and 180 nmwith a 0.2 nm step resolution. To im-
prove accuracy 5 scanswere averaged. Peptideswere dissolved in 10mM
Hepes (pH7.4) to aﬁnal concentration of 100 μM. Spectraweremeasured
in the absence and presence of 1 mM sodium dodecyl sulfate (SDS) and
1 mM dodecylphosphocholine (DPC) (Avanti Polar Lipids, Alabaster,
USA)mimicking cancer and healthymammalianmembranes, respective-
ly. The respective peptide to surfactant molar ratios were 1:25 and 1:100.
Background signals were abstracted aftermeasurements [31]. Percentage
secondary structure calculations were done using Dichroweb, CDSSTR
Convolution Program using reference set 7 [34–36].
2.6. Spectroscopy with model membranes
Leakage and Trp quenching experiments with vesicles were
performed using a SPEX Fluoro Max-3 spectroﬂuorimeter (Jobin-Yvon,
Longjumeaum, France) and spectra were analyzed with Datamax
software.
2.6.1. ANTS/DPX leakage
Leakage of aqueous contents from liposomes composed of
POPS (1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine) or POPC
(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) was determined
using the 8-aminonaphthalene-1,3,6-trisulfonic acid/p-xylene-bis-
pyridinium bromide (ANTS/DPX) assay. Lipid ﬁlms were prepared,
hydrated, measured and analyzed, as described previously [31,37,38].
2.6.2. Trp quenching by acrylamide carrying vesicles
Acrylamide carrying POPC liposomes and pure POPC liposomeswere
prepared following the protocol for ANTS/DPX containing vesicles
described previously [31,37,38] with the exception of the hydration
buffer. POPC lipid (20 mg) ﬁlms for acrylamide carrying liposomes
were hydrated with 1 ml 10 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid), 68 mM NaCl, 0,4 M acrylamide,
pH 7.4, following a standard protocol by incubation at 30 °C with inter-
mediate vigorous vortexing for 1 min every 15 min for 2 h. Following
the same protocol pure POPC liposomes were prepared by hydration
of POPC lipid ﬁlms in buffer 10 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid), 68 mM NaCl, at pH 7.4 without
acrylamide.
Subsequently, the dispersions were extruded 20 times through a
polycarbonateﬁlter (Millipore— Isopore™) of 0.1 μmpore size to obtain
LUVs. Unilamellarity and size were tested by X-ray and dynamic light
scattering, respectively. The acrylamide encapsulating vesicles were
separated from free acrylamide by exclusion chromatography using a
column ﬁlled with Sephadex™ G-75 (Amesham Biosciences, GE
Healthcare, Glattbrugg, Switzerland) ﬁne gel swollen in an isosmotic
buffer (10mMHEPES, 140mMNaCl, pH 7.4). The void volume fractions
were collected and the phospholipid concentration was determined by
phosphate analysis [37].
The ﬂuorescence measurements were performed in 2 ml of the
isosmotic buffer in a quartz cuvette at room temperature. Peptides
were diluted with the isosmotic buffer to a ﬁnal ﬂuorescence intensity
of 105–106. Aliquots of the acrylamide carrying POPC were added to a
ﬁnal peptide to lipid ratio of 1:25 and incubated for 30min. Tryptophan
ﬂuorescence spectra were obtained at room temperature using an
excitation wavelength of 282 nm and a slit width of 5 nm for excitation
and emission monochromators before and after addition of lipid.
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For preparation of liposomes 1 mg of respective phospholipid stock
solution was dried under a stream of nitrogen and stored in vacuum
overnight to completely remove organic solvents. The dry lipid ﬁlm
was then dispersed in phosphate buffered saline (PBS, 20 mM NaPi,
130 mM NaCl, pH 7.4) and hydrated at a temperature well above the
gel to ﬂuid phase transition of the respective phospholipid under inter-
mittent vigorous vortex-mixing. The lipid concentration was 0.1 wt.%
for calorimetric experiments. Hydrationwas carried out in the presence
or absence of peptides at a lipid-to-peptide ratio of 25:1 using a protocol
described for 1,2-dipamitoyl-sn-glycero-3-phospho-L-serine (DPPS)
[39]. Brieﬂy hydration of DPPS ﬁlms was performed at 65 °C for 2 h
with vortexing for 1 min every 15 min. DPPC liposomes were hydrated
at 50 °Cwith vortexing every 15min for 2 h. The fully hydrated samples
were stored for at least 1 h at room temperature until measurement.
DSC experiments were performed with a differential scanning calorim-
eter (VP-DSC) from MicroCal, Inc. (Northhampton, MA, USA). Heating
scans were performed at a scan rate of 30 °C/h (pre-scan thermostating
30min)with aﬁnal temperature of approximately 10 °C above themain
transition temperature (Tm) and cooling scans at the same scan rate
(pre-scan thermostating 1min)with a ﬁnal temperature approximately
20 °C below Tm. The heating/cooling cycle was performed three times.
Enthalpies were calculated by integration of the peak areas after
normalization to phospholipid concentration and baseline adjustment
using the MicroCal Origin software (VP-DSC version).
2.8. Zeta potential
Zeta potentials were determined with a Zetasizer Nano ZSP
(Malvern Instruments, Herrenberg, Germany) by determining the
electrophoretic mobility and applying the Henry equation. The zeta
potential was calculated according to the Smoluchovski model used
for aqueous solutions. Cells were detached freshly before measurement
by addition of accutase. Approx. 5 ∗ 104 cells were suspended in 1 ml
10 mM Hepes, 2 mM CsCl, pH 7.4. If added, peptide or Ca2+ concentra-
tionwas 1 μM, respectively. Threemeasurements were performed after
5 min of incubation at 37 °C in Cell DTS1070 disposable folded capillary
cells (Malvern) with 10–100 runs and 60 s delay between measure-
ments. Attenuation and voltage selection was automatic, analysis was
auto-mode.
3. Results
Recently we demonstrated that human lactoferricin derivatives are
highly active against cancer cell mimetics as well as against melanoma
cells in vitro [31]. In this study we report on the different modes of
action of hLFcin derivatives against cancer and non-cancer cells. The
eight studied peptides (Table 1) can be divided in three groups. The
ﬁrst group is derived from the amino acid stretch 21–31 of hLFcin,
termed LF11 [28,29,31], comprising peptides LF11-316, LF11-318 and
LF11-322, which are 9–11 amino acids long. These peptides haveTable 1
Overview of peptide sequences, net charge and positive charges of hLFcin derivatives.
Peptide Sequence Group Length [aa]/net
charge/no. of R
LF11-322 PFWRIRIRR-NH2 1 9/+5/4R
R-DIM-P-LF11-322 PFWRIRIRR-P-RRIRIRWFP-NH2 2 19/+9/8R
LF11-318 FWQRRIRRWRR-NH2 1 11/+7/6R
DIM-LF11-318 FWQRRIRRWRR-FWQRRIRRWRR-NH2 3 22/+13/12R
LF11-316 RWKRINRQWF-NH2 1 10/+5/3R
R-DIM-LF11-316 RWKRINRQWF-FWQRNIRKWR-NH2 2 20/+9/6R
R-DIM-LF11-337 PFWRRRIRIRR-RRIRIRRRWFP-NH2 3 22/+13/12R
RW-AH WWRRWWRRWRRWWRRWWR-NH2 3 18/+10/9R
Aa, amino acid; no., number.already been reported to exert antibacterial activity [30,40], but are
within this study tested for antitumor activity. The second group
comprises di-peptides that are derived from the ﬁrst group, such as
(retro) repeat derivative with a P(roline) linker, R(etro)-DIM-P-LF11-
322 [31] or (retro) repeat derivative without a P(roline) linker,
R-DIM-LF11-316. The third group consists of di-peptides derived of
LF11, such as the repeat derivative DIM-LF11-318, the (retro) repeat
derivative, R-DIM-LF11-337 and the non-LF11 derived synthetic non-
di-peptide consisting of only alternating arginines (R) and tryptophans
(W), RW-AH (Amphipathic Helix), as a mimic of an ideal membrane
active peptide. The peptides of the different groups are in the following
described to differ in length, structure, activity and selectivity for cancer
cells, targets and killing modes.
3.1. Toxicity and mechanistic studies
3.1.1. Membrane disintegration and time dependence — PI-uptake-cell
death
Cytotoxic activity of thepeptides towardsmelanomacells of primary
(SBcl-2) andmetastatic lesions (WM164), a melanoma cell line (A375),
a rhabdomyosarcoma cell line (TE671), a glioblastoma cell line
(U-87mg) and their healthy counterparts differentiated non-
tumorigenic melanocytes and normal human dermal ﬁbroblasts (NHDF)
was determined by measurement of PI-uptake, which is an indication
for the loss of cell membrane integrity and cell death (Fig. 1, Table 2).
Cells were incubated in respective media containing serum for up to 8 h
in the presence of peptides at 20 μM peptide concentration.
Short peptides LF11-322, LF11-316 and LF11-318, reported to be
active against Escherichia coli and bacterial lipid model systems [28,30,
40] were shown in this study and previously (LF11-322) [31] to exert
only negligible antitumor activity against the different tested cancer
types (b30%, see Fig. 1). The (retro) di-peptides R-DIM-P-LF11-322,
R-DIM-LF11-316 and DIM-LF11-318, as well as the synthetic peptide
RW-AH however exhibited highly increased activity against all human
cancer cell lines (80–100% after 8 h of incubation) with no preference
of a certain cancer type, though with different velocity. Accordingly
Fig. 1 shows that the cancer active di-peptides (second group) R-DIM-
P-LF11-322 and R-DIM-LF11-316 do not reach 50% killing of cancer
cells before 2–4 h of incubation. Contrary the di-peptides of the third
group DIM-LF11-318 and RW-AH reach 50% killing up to 1 h of peptide
incubation, however against all cell types, cancer as well as non-cancer
cells, indicating fast killing and no selectivity only for cancer cells.
The non-active short peptides LF11-322, -316 and -318 and the
slowly but highly cancer active peptides of the second group R-DIM-P-
LF11-322 and R-DIM-LF11-316 however were not shown to be toxic
for non-cancer cells as melanocytes and normal human dermal
ﬁbroblasts (NHDF). Fig. 1 reveals high speciﬁcity of the peptides of the
second group for cancer cells of up to 13-fold for R-DIM-P-LF11-322
(SBcl-2 over melanocytes) and 4.5-fold for R-DIM-LF11-316 (A375
over NHDF) (see LC50 PI, Table 2).
Correlation of slow killingwith speciﬁcitywas also conﬁrmed by live
microscopic inspection of the melanoma cell line SBcl-2 (data not
shown) revealing different killing velocity of the speciﬁc peptide
R-DIM-P-LF11-322 and the non-speciﬁc peptide DIM-LF11-318. Only
minor membrane damage (PI-uptake) of SBcl-2 and no damage of
NHDF by R-DIM-P-LF11-322 were observed after 1 h, whereas the
non-speciﬁc peptide DIM-LF11-318 had already killed all cells of
SBcl-2 and NHDF in the same time. This is comparable to cell toxicity
on SBcl-2 by R-DIM-P-LF11-322 after 8 h of incubation. R-DIM-P-
LF11-322 did not cause cell damage of NHDF after 8 h.
3.1.2. MTS — cell viability
To determine long-term toxicity of peptides on melanoma or
melanocytes (or dermal ﬁbroblasts), a MTS cell proliferation assay was
used to elucidate cell viability upon 24 h after incubation with variant
peptide concentrations (LC50 MTS, Table 2). As shown, LF11-322 affects
Fig. 1. PI-uptake of various cancerous and non-cancerous cell lines upon incubation with 20 μM peptide: Time dependent (1–8 h) cytotoxic activity of LF11-322, LF11-316, LF11-318,
R-DIM-P-LF11-322, R-DIM-LF11-316, DIM-LF11-318 and RW-AH against primary lesions of non-tumorigenic melanoma (skin cancer) cell line SBcl-2, melanoma metastases WM164,
differentiated control cells of primary cultures ofmelanocytes of foreskin, rhabdomyosarcoma (soft tissue cancer) cell line TE671, glioblastoma (brain cancer) cell line U-87mg and normal
human dermal ﬁbroblast cell line NHDF at 20 μM peptide concentration is shown; n.d. not determined.
Table 2
Comparison of LC50 values [μM] of treated melanoma, melanocytes and ﬁbroblasts
determined through PI-uptake (8 h) and MTS cell viability assay (24 h).
Peptide Melanoma A375
(*SBcl-2)
Dermal ﬁbroblasts NHDF
(*Melanocytes)
LC50 PI [μM] LC50 MTS [μM] LC50 PI [μM] LC50 MTS [μM]
LF11-322 (*N80) (*N100) (*N80) N100
R-DIM-P-LF11-322 9.5 ± 0.3
(*5.9 ± 0.3)
23.3 ± 1.7
(*10.4 ± 0.7)
65.1 ± 2.5
(*N80)
65.1 ± 0.3
R-DIM-LF11-316 6.5 ± 0.4 21.0 ± 1.2
(*16.0 ± 0.5)
33.2 ± 0.7 61.8 ± 0.1
R-DIM-LF11-337 3.5 ± 0.4 12.3 ± 1.3
(*5.0 ± 0.4)
11.7 ± 3.2 22.8 ± 0.1
DIM-LF11-318 3.8 ± 0.5 9.3 ± 0.8
(*9.4 ± 0.5)
2.2 ± 0.9
(*14.0 ± 0.6)
13.9 ± 0.4
RW-AH 4.5 ± 0.02 8.4 ± 0.5
(*4.6 ± 0.2)
10.0 ± 0.4 9.6 ± 0.2
Data for PImeasurements from at least seven and forMTS from at least three experiments
are presented as mean ± SD.
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R-DIM-P-LF11-322 and R-DIM-LF11-316 exhibit highly increased
cancer toxicity evidenced by LC50 SBcl-2 of 10 μM or 16 μM, respectively
(Table 2), whereas viability of ﬁbroblasts NHDF is less reduced with
6.5-fold or 3.9-fold speciﬁcity for cancer cells exerted by the respective
peptides. DIM-LF11-318, DIM-LF11-337 and RW-AH also show high
activity against cancer cells, however as well against non-cancer cells
conﬁrming their low selectivity demonstrated by the PI uptake studies
shown in Fig. 1 (Table 2) with only 1–2 fold selectivity for cancer cells.
3.1.3. Morphology of dying cells, caspase-3/7 activity and TUNEL assay —
apoptosis or necrosis
As observed in the PI-uptake studies (Fig. 1) the selective peptides
R-DIM-P-LF11-322 and R-DIM-LF11-316 were killing cancer cells
more slowly compared to the non-speciﬁc peptides DIM-LF11-318 and
RW-AH. Delayed cell death can be a hint for killing via apoptosis. This
notion was conﬁrmed by the observation of shrinking and apoptotic
like blebbing of rhabdomyosarcoma cells (TE671) and melanoma cells
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of the cells with the speciﬁc peptide R-DIM-P-LF11-322 (Fig. 2A1 and
A2, arrows indicate appearance of blebs upon incubation with peptide).
The non-speciﬁc peptide DIM-LF11-318 induced a fast killing and
slight swelling of the melanoma cells (SBcl-2) with visible lyses of
the membrane during the PI-uptake (Fig. 2A3), being characteristic for
uncontrolled killing via necrosis.Fig. 2. A: PI-uptake of cancer cells indicating different killing mechanisms by the speciﬁc pepti
(A3: SBcl-2). Overlay of ﬂuorescencemicrographs and bright ﬁeld are shown at the left (0min p
peptide incubation. The respective bright ﬁeld pictures with peptide incubation are shown in
shrinking of rhabdomyosarcoma cells (TE671) (A1) after 360 min of incubation and melanom
in bright ﬁeld (middle). Signs of necrosis by faster killing (1 h), swelling and membrane lyses o
ﬁeld (middle) and overlay with ﬂuorescence (right) are shown. B: Fold caspase-3/7 activity (to
the peptide R-DIM-P-LF11-322 (black bars) and % LDH-release (bottom) upon 2 h of incubation
peptide concentrations indicating cell damage and killing via necrosis by DIM-LF11-318. C: DNA
with 10 μM R-DIM-P-LF11-322 (C2) and with 10 μM DIM-LF11-318 (C3). On the left side FIT
R-DIM-P-LF11-322 (C2). In themiddle bright ﬁeld pictures indicatemembrane disintegration in
pictures of BF, PI-ﬂuorescence (red) and FITC-labeled DNA-fragments are shown.Further evidence is given by results obtained for caspase-3/7
activity. Melanoma cells are known to block apoptosis by inhibiting
the activation of caspase-3 and -7 [13,41]. As illustrated in Fig. 2B
(upper bar diagram) the slowly killing peptide, R-DIM-P-LF11-322
(black bars), which had shown induced apoptotic membrane blebbing,
clearly displayed increased caspase-3/7 activity of SBcl-2 (2–3-fold of
control) after 4 h of incubation with the peptide at concentrations ofde R-DIM-LF11-322 (A1: TE716, A2: SBcl-2) and the non-selective peptide DIM-LF11-318
eptide incubation) and the right side; A1: 360min peptide incubation, A2 and A3: 60 min
the middle. Signs of killing via apoptosis by appearance of blebs (middle, arrows) and
a cells (SBcl-2) (A2) after 60 min of incubation with 20 μM R-DIM-LF11-322 are shown
f SBcl-2 melanoma cell line after 1 h of incubation with 20 μM DIM-LF11-318 (A3) bright
p) of melanoma cell line SBcl-2 after 4 h of incubation indicating induction of apoptosis by
with peptides R-DIM-P-LF11-322 (black bars) and DIM-LF11-318 (gray bars) at different
fragmentation of melanoma cell line SBcl-2 upon 2 h of incubation without peptide (C1),
C-labeled DNA-fragments (green) are shown indicating apoptosis upon incubation with
the presence of R-DIM-P-LF11-322 (C2) andDIM-LF11-318 (C3). On the right side overlay
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show any increased levels of caspase-3/7 activity at any concentration,
suggesting other killing mechanism than apoptosis. In combination
with the simultaneous measurement of the release of LDH (lactate
dehydrogenase), a soluble cytosolic enzyme that is released into the
culture medium, loss of membrane integrity resulting from either
apoptosis or necrosis can be evidenced (Fig. 2B, lower bar diagram).
In the case of the peptide DIM-LF11-318 a strongly increased LDH-
release was observed, indicative of severe membrane disintegration,
already in the presence of low concentrations of the peptide (gray
bars), suggesting necrosis to be induced by this peptide. As can be
further seen in Fig. 2B above 40 μM also R-DIM-P-LF11-322 (black
bars) induced an increase of LDH-release, whereas no caspase-3/7
activity was observed.
Further supporting results were obtained with a direct in situ DNA
fragmentation assay, another possibility to differentiate between
necrotic and apoptotic killing. Fig. 2C displays microscopy images of
melanoma cell line SBcl-2 in the absence (Fig. 2C1) and presence of
peptides R-DIM-P-LF11-322 (Fig. 2C2) and DIM-LF11-318 (Fig. 2C3). On
the left side FITC-labeled DNA-fragments (green) are shown indicating
potential apoptosis. No green ﬂuorescence signal of the FITC-dUTP
labeled DNA fragments is visible without peptide and in the presence
of 10 μM DIM-LF11-318 (2 h of incubation) indicating absence of
apoptosis. Contrary SBcl-2 cells exposed to speciﬁc peptide R-DIM-P-
LF11-322 (10 μM, 2 h of incubation) exhibit distinct green ﬂuorescence
signals of the FITC-dUTP labeled DNA fragments indicative for apoptosis
(Fig. 2C2). In the middle bright ﬁeld (BF) pictures indicate membrane
disintegration only in the presence of R-DIM-P-LF11-322 (Fig. 2C2)
and DIM-LF11-318 (Fig. 2C3). On the right side overlay pictures of BF,
PI-ﬂuorescence and FITC-labeled DNA-fragments are shown. Red
ﬂuorescence occurs in any cases, since the experiment involves ﬁxation
of cells, different to the studies described before, where PI-uptake was
only peptide induced. In the case of cells incubated with DIM-LF11-
318 the red ﬂuorescence is less intense (more diffuse), sincemembrane
lyses upon incubation with this peptide induces degradation and
release of DNA fragments.
Selectivity and structural studies—circular dichroism spectroscopy
analysis of the peptides LF11-322 and R-DIM-LF11-322 was reported
in a recent study [31]. Fig. 3A now compares the CD-structural results
of R-DIM-P-LF11-322, R-DIM-LF11-316 and DIM-LF11-318. R-DIM-P-
LF11-322 in solution is mainly unstructured and is showing β-sheet
conformation and turns to a similar extent [31]. Since CD-experiments
in lipidic environment as POPS or POPC deliver rather noisy data, SDS
was taken as negatively charged cancer and DPC as neutral non-
cancer mimic. In the presence of the cancer mimic SDS and at a
peptide-to-lipid ratio of 1:25 R-DIM-P-LF11-322 exhibits a signiﬁcant
increase of β-sheet conformation (30 to 41%). The structure of the
peptide in the presence of the healthy mimic DPC is comparable to its
structure in solution, indicating a structure dependent cancer selective
toxicity of this peptide, which has already been shown previously [31].
Similarly, the cancer-speciﬁc peptide R-DIM-LF11-316 only showed a
signiﬁcant change in secondary structure in the presence of the cancer
mimic SDS, the α-helical conformation thereby increased from 2% to
22%. In contrast, the non-selective peptide DIM-LF11-318 changes its
conformation, though unstructured in solution, massively in the
presence of both, the cancer and the non-cancer mimic system. This
goes in hand with its non-selective activity. Further it changes its
conformation of 6% α-helical to 75% α-helical in the presence of SDS
and 72% in the presence of DPC. Also the structure predictions
performed by the program PEP-FOLD [42–44] (http://bioserv.rpbs.
univ-paris-diderot.fr/PEP-FOLD/) (Fig. 3 colored structures in center)
reveal a β-strand conformation for R-DIM-P-LF11-322 with a loop,
two α-helices separated by a loop for R-DIM-LF11-316 and α-helix for
DIM-LF11-318 without a loop, which is in agreement with CD spectra
of the peptides in the presence of model systems. PEP-fold structure
predictions for likewise less selective peptide R-DIM-LF11-337 andnon-selective peptide RW-AH as well show helical structures without
a loop, more extended in case of the latter. The selectivemother peptide
hLFcin reveals conﬁrmation with a loop between an α-helical and an
extended non-structured part, which is in agreement with structural
data reported before [27]. Also the selective peptide R-DIM-LF11-316
revealed a conformation with a loop, though in this case breaking two
α-helical segments. As can be seen in Fig. 3B the loop structures relate
to high cancer speciﬁc peptides being toxic for the melanoma cell line
A375 and the glioblastoma cell line U-87mg but non-toxic for normal
human dermal ﬁbroblasts NHDF, whereas the non-speciﬁc peptides
exhibit α-helical structures without a loop exhibiting toxicity for all
cell types. Fig. 3B also demonstrates the highly increased activity of
R-DIM-P-LF11-322 and R-DIM-LF11-316 compared to the activity of
their original parent peptide hLFcin of up to 10-fold in A375 and 2–
3-fold in U-87mg.
3.2. Potential molecules for peptide interaction
The studied peptides exhibit positive net charges (Table 1), mainly
via arginines (and lysines), a potential target thereof are negatively
charged cell components on the surface and subsequently in the inside
of cells.
As known, cancer cell surfaces differ from that of non-cancer cells by
increased exposure of negatively charged PS [7,11], whichmight repre-
sent a speciﬁc target for the cationic peptides. Other negative charges
exposed are present on cancer and non-cancer cells, as sialic acid,
being part of glycoproteins (mucins), partially overexpressed by some
cancer types [45–47]. Changes in surface expression of glycosaminogly-
cans like e.g. heparan or chondroitin sulfate also present on cancer and
non-cancer cells are characterized by partially increased or decreased
levels on cancer surfaces of different cancer types [7].
3.2.1. Zeta potential of cancer and non-cancer cell surfaces — electrostatic
interactions
As demonstrated by measurement of the zeta potential of non-
cancer cells NHDF, low tumorigenic melanoma cells from primary
lesions SBcl-2 and melanoma cells from metastases WM164 the
zeta potential decreases with malignity from quasi neutral for non-
malignant NHDF (0 mV) to −25 mV and to −35 mV for SBcl-2 and
metastases WM164, respectively (Fig. 4A). The addition of the peptide
R-DIM-P-LF11-322 to the cancer cells shifted the zeta-potential signiﬁ-
cantly (by about 10 mV) to neutral levels, such as the addition of Ca2+
ions. This strongly indicates an electrostatic interaction between the
positive charges of the peptide and negative charges of the cancer
surface. The addition of the peptide DIM-LF11-318 shifts the zeta
potentialmore strongly (by about 20mV), probably due to hydrophobic
additional to the electrostatic interactions. It has to be mentioned, that
peptide incubation was limited to 5 min, to avoid membrane lyses
that would expose PS, normally on the inside of the cell membrane,
overlapping with the changes in zeta potential by binding of peptides
to the outside. Addition of Ca2+ or peptides R-DIM-P-LF11-322 and
DIM-LF11-318 with neutral surface of non-cancer cells NHDF indicate
no electrostatic interactionwith the surface of the cells due to negligible
shifts of the zeta potentials observed.
However as demonstrated in Fig. 4B for longer peptide interaction
only the toxicity of the speciﬁc peptide R-DIM-P-LF11-322 on melano-
ma cell line SBcl-2 is signiﬁcantly affected by the presence of Ca2+
ions. For example, after 4 h the PI-uptake of SBcl-2 in the presence of
20 μM R-DIM-P-LF-322 is reduced from 80% at normal level of Ca2+
(0.4 mM) to 20% at the highest concentration of Ca2+ tested (20 mM)
indicating a strong competition of the peptide and Ca2+ for a negatively
charged target on the cancer membrane. After 8 h however the Ca2+-
level does no longer affect the peptide activity, the peptide can either
displace the Ca2+ or after 8 h Ca2+ has already been internalized.
Activity of the non-speciﬁc peptide DIM-LF11-318 however does not
seem to be affected by Ca2+. Only very high Ca2+-levels have an impact
Fig. 3. Correlation of peptide structure and cancer speciﬁc cytotoxicity. A: Secondary structures of R-DIM-P-LF11-322 [31], R-DIM-LF11-316 and DIM-LF11-318 in Hepes buffer (black
lines) or presence of SDS (gray lines) and DPC (light gray lines) at peptide to surfactant ratios of 1:25 calculated from CD spectra using Dichroweb, CDSSTR Convolution Program
[34–36]. Theα-helical content is shown in black at the bottom;β-turns are shown in light gray; turns are shown in dark gray; randomcoil structures are shown inwhite at the top. Speciﬁc
peptides R-DIM-P-LF11-322 and R-DIM-LF11-316 change their secondary structure only in the presence of the cancermimic SDS. The less speciﬁc peptide DIM-LF11-318 shows a change
in secondary structure in the presence of both, SDS and DPC. B: The bars show cytotoxicity on cell lines of melanoma A375, glioblastoma U-87mg and normal human dermal ﬁbroblasts
NHDFupon 8 hof incubationwith 20 μMparent peptide hLFcin and cancer speciﬁc derivatives R-DIM-P-LF11-322 and R-DIM-LF11-316 and less speciﬁc derivatives R-DIM-LF11-337, DIM-
LF11-318, as well as synthetic peptide RW-AH. On top PEP-FOLD secondary structure predictions [42,44] of peptides are shown. HLFcin is the only peptide containing a disulﬁde bridge. R-
DIM-PEP-LF11-322 is the only peptide being predicted to form a β-sheet. Positively charged amino acids like Arg are colored in red,more hydrophobic amino acids like Trp, Phe and Ile are
colored in pink, violet and blue, respectively. Peptides adopting a predominantly helical (amphipathic) structure exhibit non-selective activities on cancer cells and normal cells, as well.
Peptides comprising a β-sheet or a helical structure interrupted by a turn (loop) act more highly speciﬁc on cancer cells.
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less dependent on a negatively charged target on the cell surface than
R-DIM-P-LF11-322, which might explain the interaction with cancer
and non-cancer cells.
3.2.2. Phosphatidylserine — a negatively charged phospholipid only
exposed on the surface of cancer cells
A potent target of anticancer peptides is described to be the nega-
tively charged lipid phosphatidylserine [7,11] speciﬁcally exposed by
cancer cells [13,15]. Therefore liposomal mimics of human cancerous
membranes are applied, as DPPS or POPS to study the peptide cancer
membrane interaction. As reported previously the speciﬁc peptideR-DIM-P-LF11-322 induces membrane permeabilization of POPS
bilayers whereas the non-cancer mimic POPC is not affected [31]. As
demonstrated in Fig. 5A ANTS/DPX leakage of liposomes composed of
the cancer mimic POPS is, besides by R-DIM-P-LF11-322, only induced
by other in vitro active (retro-) di-peptides as R-DIM-LF11-316,
R-DIM-LF11-337, DIM-LF11-318 and the synthetic peptide RW-AH.
The short parents LF11-322, -316 and -318, which are not active
in vitro, in accordance show onlyminor induction ofmembrane leakage
of POPS. Membrane interaction with PS is also conﬁrmed by differential
scanning calorimetry (DSC) (Fig. 5B), where severe membrane pertur-
bation of DPPS was shown by the in vitro active peptides. Upon incuba-
tion with the di-peptides and RW-AH the transition temperatures (Tm)
Fig. 4. Cell zeta potential and interaction with positive charges. A: Zeta potential of non-cancer cells NHDF (normal human dermal ﬁbroblasts) compared to melanoma cancer cells of
primary lesions SBcl-2 and metastases WM164 in the absence (black lines) and in the presence of 1 μM peptide R-DIM-P-LF11-322 (gray lines), 1 μM DIM-LF11-318 (intermittent
black lines) and in the presence of 1 μM Ca (intermittent gray lines) (5 min incubation time). Cancer cells exhibit more highly negative zeta potentials in comparison with normal
ﬁbroblasts. Peptides and calcium can compensate the negative zeta potential indicating an interaction of peptides and the negatively charged surface of the cancer cells. The addition
of Ca2+ or peptides to normal ﬁbroblasts does however not show any interaction on the cell surface. B: Cell death in the presence of peptides affected by increasing amounts of Ca2+.
The activity of the speciﬁc peptide R-DIM-P-LF11-322 (upper) is affected by increasing amounts of Ca2+, indicating sole interaction with negative charges on the surface of cancer
cells. The activity of the non-speciﬁc peptide DIM-LF11-318 (lower) is less dependent on a negative cell surface.
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grees. Cooperativity was increased, indicated by an increase of the
half-width (T1/2). The transitions were mainly split in 2 or more peaks,
due to peptide affected lipid domains, where the lower temperature do-
main is probably more highly enriched in peptide. In some cases also a
strong decrease of the phase transition enthalpy (ΔHcal) indicated se-
vere membrane destabilization.
3.2.3. Phosphatidylcholine— a zwitterionic (neutral) phospholipid present
on the surface of cancer and non-cancer cells
As shownbefore, interactionwith the omnipresent (cancer andnon-
cancer) lipid phosphatidylcholine can go in handwith toxicity on cancer
and non-cancer cells [31]. ANTS/DPX leakage of liposomes composed of
the non-cancer mimic POPC indeed revealed no membrane perme-
abilization by the cancer speciﬁc peptide R-DIM-P-LF11-322 (Fig. 5A).
This is in correlation with its non-toxicity on non-cancer membranes.
On the other hand strong membrane permeabilization by the non-
speciﬁc peptide RW-AH (already 70% leakage at 2 μM RW-AH) is in
correlation with its toxicity on ﬁbroblasts and melanocytes. This result
was also conﬁrmed by DSC, showing no interaction by R-DIM-P-LF11-
322, but only perturbation of PC bilayers by RW-AH (Fig. 5B). In the
presence of the peptide RW-AH the DPPC liposomes were massively
inﬂuenced, the phase transition was nearly completely abolished in
the temperature range studied. Surprisingly, it could be shown that
the non-speciﬁc peptide DIM-LF11-318 however, though interacting
in vitro with non-cancer membranes, did not cause membrane perme-
abilization nor membrane perturbation of PC bilayers, such as the non-
speciﬁc peptide RW-AH. As demonstrated in Fig. 6 DIM-LF11-318 is
however able to penetrate POPC bilayers though apparently without
causing severe membrane damage (Fig. 5B). Inside the cell, DIM-LF11-
318 probably may cause damage by contact with other (inner) mem-
brane components or interact with other negatively charged inner
targets (see discussion Fig. 7). Thiswas indicated by a decrease of nearly50% of the Trp ﬂuorescence of the peptide DIM-LF11-318 in the
presence of POPC liposomes containing the quencher acrylamide only
inside (Fig. 6) compared to the presence of PC liposomes containing
only buffer. This can only be the case if the peptide DIM-LF11-318
penetrates the PC membrane getting access to the quencher. The emis-
sion wavelength did not show any blue-shift, conﬁrming no membrane
permeabilization.Whereas the speciﬁc peptides R-DIM-P-LF11-322 and
R-DIM-LF11-316 showed no change in ﬂuorescence intensity in the
presence of both vesicle types, containing acrylamide or containing
buffer. No blue-shift was revealed indicating no interaction at all with
the healthy mimic correlating with its non-interaction with healthy
cells. Also in accordance with the demonstrated strong interaction of
RW-AH with PC bilayers in Fig. 5 by permeabilization and perturbation
Fig. 6 shows entrance of RW-AH into PC bilayers and thereby access to
acrylamide and/or release of acrylamide. The induced blue-shift of
about 10 nm (Fig. 6) conﬁrms the strong membrane perturbation of
PC bilayers (Fig. 5).
3.2.4. Sialic acid — a negatively charged molecule increased on surfaces of
cells of some cancer types
Probable interaction with other negatively charged membrane
components, as e.g., sialic acid, being part of glycoproteins, which are
partially overexpressed by some cancer types [45–47], was studied.
Therefore neuraminidase from C. perfringens to malignant melanoma
cell line A375, melanoma metastases WM164, glioblastoma cell line
U-87mg and the rhabdomyosarcoma cell line TE671 to cleave off
terminal sialic acid residues which are α-2,3-, α-2,6- or α-2-8-linked
to oligosaccharides, glycolipids or glycoproteins was applied (Table 3).
However cleavage of sialic acid residues from the cancer types tested
did not signiﬁcantly change activity of the studied peptides up to 8 h
of incubation, indicating that sialic acid is neither a main target for the
studied peptides nor able to protect the cancer cells from the toxic effect
of peptides. Only in the case of U-87mg cells removal of sialic acid
Fig. 5. Interaction of peptides with cancer and non-cancer membrane model systems. A: ANTS/DPX leakage of LUVs composed of cancer mimic POPS (top) or non-cancer mimic POPC
(bottom) as a function of concentration of LF11-322 (●), R-DIM-P-LF11-322 (○), LF11-318 (▼), DIM-LF11-318 (Δ), LF11-316 (■), R-DIM-LF11-316 (□), R-DIM-LF11-337 (♦) and
RW-AH (◊). Concentration of LUVs was 50 μM and temperature was kept at 37 °C during measurements. Complete lyses was determined by addition of Triton X-100 and zero levels
correspond to ﬂuorescence before peptide addition. B: DSC thermograms of cancermimic DPPS (top) or non-cancermimic DPPC (bottom) in the absence (black) and presence of elevated
peptides (gray) (25:1, lipid-to-peptide molar ratio). For clarity, the DSC curves were displayed on the ordinate by an arbitrary increment. Peptides active in vitro are active on the model
system PS. Only the di-peptides R-DIM-P-LF11-322, R-DIM-LF11-316, R-DIM-LF11-337, DIM-LF11-318 and the synthetic peptide RW-AH show strong interaction with the cancer mimic
system PS. Only the synthetic peptide RW-AH shows permeabilization and perturbation of PC membranes.
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by approximately 10%. On the surface of these cancer cells sialic acid
might slightly shield the cells from the peptide access to the cell
membrane.
3.2.5. Heparin and chondroitin sulfate — a negatively charged molecule
increased or decreased on surfaces of cancer cells
Other negative charges exposed on the surface of cancer, but also of
non-cancer cells are heparan sulfate (HS) and chondroitin sulfate (CS)
[7]. Competition with heparin or chondroitin sulfate (CS) was therefore
tested by addition of exogenous heparin and CS in concentrations of
1 μg/ml and 10 μg/ml to melanoma cells A375 (Table 4). No signiﬁcant
effect on the di-peptide activity was observed. The activity of the short
peptides LF11-322 and LF11-318 was however increased to some
extent. Higher amounts of heparin were not used, since at elevated
concentrations observed effects could become non-speciﬁc because HS
might interfere with electrostatic interactions in general [48]. The
results indicate neither a potent target nor a protective function by HS
and CS on peptide activity.
4. Discussion
Recently it has been shown that hLFcin derivatives can target the
negatively charged phospholipid phosphatidylserine [31] which is
speciﬁcally exposed by cancer cells and metastases [13,15,49]. In this
previous study we have demonstrated that an enhanced membraneinteraction of the peptide R-DIM-P-LF11-322 (a di-retro-peptide
derived from the short membrane active peptide LF11-322) [29,30]
with the cancer mimics anionic PS and mixtures of PS and neutral PC
correlates with highly increased activity againstmelanoma cells where-
as increasing interaction of N-acyl-LF11-322 with the healthymimic PC
correlated with decreased speciﬁcity indicated by intensiﬁed interac-
tion with differentiated cells like melanocytes. In the present study we
investigated the cytotoxic effects of LF11-322 and R-DIM-P-LF11-322
and other LF11 derivatives like R-DIM-LF11-316 (derived from LF11-
316), R-DIM-LF11-337 and DIM-LF11-318 (derived from LF11-318)
for cancer cell lines isolated from a primary malignant melanoma, a
melanoma metastasis, glioblastoma (brain tumor) and rhabdomyosar-
coma (soft tissue tumor) and compared to toxicity on differentiated
cells like human melanocytes and human dermal ﬁbroblasts. Further a
synthetic peptide RW-AH, comprising an alternating sequence of the
amino acids Arg and Trp, constituting an amphipathic α-helix, was
probed to determine potential characteristics for α-helical membrane
active peptides. Mechanistic studies aimed to identify the different
mode of actions (Fig. 7) of active-selective and active-non-selective
peptides. For (bovine) bLFcin derivatives it has already been reported
that that a minimum length and net positive charge are required in
order to exert an appropriate anticancer activity [50]. Expectedly, the
short peptides LF11-322 (+5), LF11-316 (+5) and LF11-318 (+7)
only induced minor cell death inducing no effect against cancer cells
even if the incubation time was extended to 8 h (Fig. 1) or 24 h (data
not shown). Partially the low activity might be related to shortness
Fig. 6. Tryptophan ﬂuorescence of peptides in the presence of POPC vesicles (small unilamellar vesicles, 100 nm)with buffer or 0.4 M quencher acrylamide (Aa) enclosed. For detection of
potential interaction of respective peptides with, respectively penetration of, POPC membranes, tryptophan ﬂuorescence was measured at an excitation wavelength of 280 nm. Dotted
vertical line representsλem, max of peptides in thepresence of the buffer. Curved lines representwavelength scans of peptides in the presence of POPC vesicles (solid line) and POPC vesicles
enclosing 0.4 M acrylamide (dotted line).
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exhibiting higher net charges, such as the di-(retro)-peptides R-DIM-P-
LF11-322 (+9), R-DIM-LF11-316 (+9), R-DIM-LF11-337 (+13) and
DIM-LF11-318 (+13) and the synthetic peptide RW-AH (+10) exhib-
ited highly increased activity against cancer cells of the skin, brain and
soft tissue. However the different peptides seem to act via different
mechanisms, since the peptides DIM-LF11-318 and RW-AH killed
signiﬁcantly faster than the di-peptides R-DIM-LF11-322 and R-DIM-
LF11-316. Strikingly the faster killing properties were not only found
to be toxic for cancer but also for differentiated cells like melanocytes
or dermal ﬁbroblasts. The different time dependence of cell killing by
the peptides indicates two different killing mechanisms as described
for other host defense peptides which mainly trigger cell death by
necrosis or by induction of apoptosis [7,11]. For triggering necrosis
peptides directly kill by disrupting the target plasma membrane, a fast
process, whereas for triggering apoptosis they have to enter the cell to
reach e.g. a mitochondrial target [11]. The fast activity of RW-AH and
DIM-LF11-318 gives strong evidence for a direct membranolytic effect
causing necrosis. Structural analysis through CD spectroscopy of
DIM-LF11-318 reveals induction of a mostly α-helical structure in the
presence of the cancer as well as the non-cancer mimic which might
also result in non-selective lyses of cells. The selective peptides
R-DIM-P-LF11-322 and R-DIM-LF11-316 obviously act via a different
mechanism. The relatively slow action combined with the observation
of membrane blebbing is an indication for membrane-mediated
apoptosis. This assumption was further proven by caspase-3/7 cleavage
studies and an apoptotic DNA-fragmentation assay. Indeed, melanoma
cells like SBcl-2 showed activation of caspase-3/7 and DNA fragmenta-
tion after incubation with rather low concentrations of R-DIM-P-LF11-322. For induction of apoptosis probably the peptide has to enter the
cell speciﬁcally via the PS exposing sites (PS-domains) on the surface
of cancer cells and further reach negatively charged targets on the
surface of cancer cell mitochondria, like phosphatidylserine and
cardiolipin. Just previously it has been shown that the LF11 derived
peptides not only interact with phosphatidylserine, but also with
cardiolipin [40]. Successive swelling of mitochondria and release of
cytochrome-C activate the caspase dependent pathway of the pro-
grammed cell death. Apoptosis is reported to be blocked inmany cancer
types as in melanoma cells by inhibition of a gene encoding Apaf-1, the
apoptotic protease activating factor-1 [41] or in B-cell-leukemia by
expression of high levels of Bcl-2, a protein that blocks apoptotic signals
[51]. Induction of apoptosis in human leukemia was also observed for
bovine LFcin by Mader et al. [52] and is probably one of the keys for
speciﬁc anticancer activity of host defense peptides. However, the
activity of the original human host defense peptide (hLFcin) is rather
low, whereas derived peptides R-DIM-LF11-322 and R-DIM-LF11-316
show signiﬁcantly increased activities against melanoma and glioblas-
toma cell lines. Interestingly R-DIM-P-LF11-322 shows an increase in
the predominant β-sheet structure in the presence of the cancer
mimic and no changes in structure in the presence of the non-cancer
cell mimic. So far, most studies report about the necessity of membrane
active peptides of formation of anα-helical structure [53,54]. However,
in our studieswe could show that only thepeptide derivatives forming a
loop structure separating 2 β-strands or 2 α-helices were able to act
speciﬁcally on cancer cells without displaying any cytotoxicity on
normal cells. Similarly it has been reported recently that membrane-
induced folding of the peptide SVS-1 is driven by electrostatic interac-
tion between the peptide and the negatively chargedmembrane surface
Fig. 7.Proposedmodeof action of cancer selective peptide R-DIM-P-LF11-322 (left) andnon-selective peptideDIM-LF11-318 (right)with cancer cellmembranes (top) andnon-cancer cell
membranes (bottom) (for description, see the Discussion section).
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the surface of cancer cells, adopting an amphiphilic β-hairpin structure
capable of membrane disruption [55].
Since PS is not the only negatively charged interaction partner on the
cell surface (for a review see [7]) other cancer cell compounds like sialic
residues or heparin or chondroitin sulfate have to be considered. In
contrast to PS these molecules however stick out of the membrane,
interaction with compounds does therefore not necessarily damage
the membrane or enable entrance to the cell. Second these molecules
are not speciﬁcally present on the surface of cancer cells, but are alsoTable 3
Inﬂuence of sialic acid cleavage from rhabdomyosarcoma cell line TE671 on cytotoxic
activity of peptides after 1 h of incubation and melanoma cell lines WM164, A375 and
glioblastoma cell line U-87mg after 8 h of incubation with 20 μM peptides.
PI-uptake [%]
Untreated TE671 Sialidase treated TE671
LF11-322 6.1 ± 5.1 4.3 ± 5.0
Untreated WM164 Sialidase treated WM164
R-DIM-P-LF11-322 36.6 ± 7.7 39.8 ± 16.9
LF11-318 27.0 ± 7.1 32.2 ± 16.0
DIM-LF11-318 67.5 ± 5.6 70.5 ± 18.0
Untreated A375 Sialidase treated A375
LF11-322 5.4 ± 4.5 13.1 ± 4.8
R-DIM-P-LF11-322 95.2 ± 3.2 93.6 ± 1.9
LF11-318 24.0 ± 14.1 17.8 ± 2.5
DIM-LF11-318 92.3 ± 7.5 89.3 ± 4.3
Untreated U-87mg Sialidase treated U-87mg
LF11-322 23.0 ± 6.5 24.5 ± 1.8
R-DIM-P-LF11-322 81.4 ± 10.2 90.7 ± 2.9
LF11-318 21.0 ± 5.9 25.4 ± 3.6
DIM-LF11-318 88.9 ± 6.0 99.7 ± 0.5present on non-cancer cells. Sialic acid, often increased on the surface
of cancer cells, might even protect cancer cells and metastases [56–58]
against anticancer drugs, besides being a target for the peptides. It was
reported that neuraminidase-treated U937 cells were less susceptible
to permeabilization by BMAP peptides, suggesting that the sialyl
moieties might be initial interaction sites of these peptides with the
cells [33]. In contrast, we could show for several cancer types that
cleavage of sialic acid moieties did not signiﬁcantly change the activity
of the studied peptides. The results indicate that the sialic residues are
not a main target or initial interaction site, nor a blocker of activity for
the peptides studied. Also the metastases WM164 were unaffectedly
sensitive to the peptides in the presence of sialic acid and absence there-
of. Proteoglycans with highly negatively charged glycosaminoglycan
side chains attached to a core protein are also expressed on the cell
surface. Two major classes of such side chains are heparan sulfate
(HS) and chondroitin sulfate (CS) [14]. HS and/or CS present on cancer
and non-cancer cells can be either decreased or increased on cancer
cells depending on cancer type [7]. HS and CS thus may be able to act
like a protection shield on the surface of cells (cancer and non-
cancer), since they protrude out of the cell membrane like a brush [59,
60], modulating cell phenotype, growth kinetics, invasiveness and
metastatic potential [61–63]. Wade et al. [64] reported for glioblastoma
(GBM) a signiﬁcant up-regulation of many proteoglycans with
differences in the tumor subtypes. Also for melanoma an up-regulation
of certain glycosaminoglycans was observed [65]. Fadnes et al. [14]
found that the anticancer activity of bovine LFcin was inhibited by hepa-
ran sulfate on the surface of tumor cells. In our studies the di-peptides
derived from hLFcin were however not inﬂuenced in their activity by
exogenous heparin or chondroitin sulfate at physiological concentrations
of 1–10 μg/ml [66,67]. Thus neither heparin nor CS, which is increased on
the surface of melanoma cells, seems to signiﬁcantly protect the cell from
the interaction with the studied di-peptides. Interestingly the activity of
Table 4
Inﬂuence of heparin and chondroitin sulfate on peptide activity against melanoma cell line A375 after 8 h of incubation with 20 μM peptides.
PI-uptake [%]
A375 +1 μg/ml
Heparin
+10 μg/ml
Heparin
+1 μg/ml
CS
+10 μg/ml
CS
LF11-322 5.4 ± 4.5 20.4 ± 8.2 14.5 ± 1.7 22.2 ± 4.1 16.0 ± 2.4
R-DIM-P-LF11-322 95.2 ± 3.2 98.4 ± 1.2 94.4 ± 2.2 99.3 ± 0.7 96.4 ± 1.7
LF11-318 24.0 ± 14.1 52.8 ± 6.5 42.6 ± 10.7 45.2 ± 15.6 44.4 ± 6.6
DIM-LF11-318 92.3 ± 7.5 100.0 ± 0.0 99.7 ± 0.4 100.0 ± 0.0 100.0 ± 0.0
2930 S. Riedl et al. / Biochimica et Biophysica Acta 1848 (2015) 2918–2931the short peptides, which are under normal conditions only minor active,
was however increased by the exogenous addition of heparin and CS.
Similarly a contribution of heparan sulfate proteoglycans to the cell
entry mechanism of e.g. cell penetrating peptides has been discussed
[48]. The short peptides might probably be stabilized by binding to
exogenous heparin.
We are proposing different scenarios based on the observed
structural properties (Fig. 7). In the presence of cancer membranes
cancer speciﬁc peptides (as R-DIM-P-LF11-322) adopt a loop structure
(CD, PEP-FOLD), interact (only) with negatively charged membrane
surfaces (zeta potential and PI-uptake with or without Ca2+), presum-
ably exposed PS [13] (cancer mimic PS, leakage and DSC). They
are able to neutralize the negatively charged surface and compete
with cations such as Ca2+. However after 8 h and at elevated concentra-
tions they have reached an inner target, probably mitochondria
to induce apoptotic killing (apoptosis studies and PI toxicity),
membrane blebbing and membrane disintegration occurs, cancer cells
die. In case of cell membranes from differentiated cells no change of
structure (CD) and no interaction with the neutral surface of normal
cells occurs (non-cancer mimic PC, zeta potential), therefore cells stay
intact.
Differently non-selective peptides (as DIM-LF11-318) form an
α-helical structure in the presence of the cancer and the non-cancer
membrane (CD) without a loop (PEP-FOLD). When they contact the
cancer membrane they can attach to negatively charged surfaces as PS
and/or neutral surfaces as PC and cause fast killing by membrane
lyses, presumably by necrosis. The interaction of the α-helical peptide
(CD) with non-cancer membranes however does not occur via
membrane lyses from the outside (non-cancer mimic PC), but via cell
penetration (PC studies with quencher) and then presumably via
induction of necrosis (lyses) from the inside of the plasma membrane.
This is comparable to the described uptake mechanism of so called cell
penetrating peptides [68,69].
In summary our studies provide evidence that speciﬁc activity
of hLFcin derived peptides depends on a slow killing mechanism, as
e.g. apoptosis, rather than killing by necrosis, interaction with PS
exposed by cancer cells, notwith PC abundant on all cell types, adoption
of a β-sheet structure in the presence of cancer cells and no changes in
structure in the presence of the non-cancer cell mimic.
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